Solara Active Pharma Sciences earnings calls.
Other · 2 quarters tracked · source-linked performance, management guidance and promise context.
Latest revenue
₹387 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
Assessment incomplete
Across 3 tracked commitments. Delivery assessment incomplete while 3 remain unresolved or evidence-limited.
Call date
2026-05-01
latest available source date
Signal trajectory
2 actual quartersCurrent read
Assessment incomplete
Across 3 tracked commitments. Delivery assessment incomplete while 3 remain unresolved or evidence-limited.
Latest source read
What changed this quarter?
Solara delivered its strongest quarter in eight quarters, with revenue of ₹392 crore (up 12% QoQ) and EBITDA of ₹61 crore (up 65% QoQ), driven by the base business which operates at 26% EBITDA margins and 54% gross margins. The base business continues to gain momentum through new customer wins and capacity utilization improvements, with 30% spare capacity available. Ibuprofen remains a drag with negative EBITDA, but management has appointed bankers to evaluate strategic options, expecting resolution in H1 FY27. The company targets becoming debt-free by FY29 and plans 4-5 DMF filings annually, though R&D benefits will only materialize from FY29 onwards. Key risk: Ibuprofen losses could persist if strategic options are delayed or unfavorable.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹387 Cr
Source date
2026-05-01
Across the record
Quarter history.
History modules